Press releases
- PTC Therapeutics to Participate at Upcoming Investor Conference
- PTC Therapeutics Announces Validation of Sepiapterin European MAA
- PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation
- PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
- PTC Therapeutics to Participate at Upcoming Investor Conferences
- PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
- PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
More ▼
Key statistics
On Monday, PTC Therapeutics Inc (BH3:BER) closed at 33.80, -16.75% below its 52-week high of 40.60, set on Jun 21, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 33.40 |
---|---|
High | 34.00 |
Low | 33.20 |
Bid | 32.40 |
Offer | 33.40 |
Previous close | 33.60 |
Average volume | 0.00 |
---|---|
Shares outstanding | 76.70m |
Free float | 74.84m |
P/E (TTM) | -- |
Market cap | 2.75bn USD |
EPS (TTM) | -7.69 USD |
Data delayed at least 15 minutes, as of Jun 17 2024 19:30 BST.
More ▼